Literature DB >> 21901319

D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test.

Samuel A Barnes1, Jared W Young, Jo C Neill.   

Abstract

RATIONALE: Impaired attention/vigilance is putatively core to schizophrenia. The dopaminergic D(1) receptor system has been reported as one of the most promising targets for improving cognition in patients with schizophrenia, with some evidence suggesting D(1) activation may improve sustained attention.
OBJECTIVES: The purpose of this study was twofold: firstly assessing the applicability of using rats in the 5-Choice Continuous Performance Test (5 C-CPT), recently validated in mice. Secondly, the effect of systemic administration of a D(1) partial agonist, SKF 38393, on task performance during baseline, and a challenge session consisting of a reduced event-rate was investigated.
METHODS: Animals were trained to perform the 5 C-CPT with performance assessed following systemic SKF 38393 (2, 4 and 6 mg/kg) vs. vehicle administration.
RESULTS: Rats could discriminate between target (requiring a response) and non-target (requiring the inhibition of response) trials within the 5 C-CPT. Moreover, SKF 38393 treatment impaired performance during the baseline session reducing target detection, yet improved performance during the reduced event-rate challenge session, increasing target detection and improving signal discrimination indicating an SKF 38393-induced enhancement of vigilance. Thus, these data suggest that activation of the D(1) system affected 5 C-CPT performance in a baseline dependent manner.
CONCLUSION: Rats can be trained to perform the 5 C-CPT, appropriately withholding from responding to non-target trials. Systemic administration of SKF 38393 impaired performance during baseline conditions. Following a task-related challenge, which reduced the event rate, activation of the dopamine (DA) D(1) system improved performance by heightening the animals' vigilance levels, quantified using signal detection theory.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901319      PMCID: PMC5870138          DOI: 10.1007/s00213-011-2460-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  59 in total

1.  Dissociation between the effects of benzodiazepine receptor agonists on behavioral vigilance and responsitivity.

Authors:  P Dudchenko; B Paul; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.

Authors:  Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten
Journal:  Nat Neurosci       Date:  2007-02-04       Impact factor: 24.884

3.  The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Cereb Cortex       Date:  1996 May-Jun       Impact factor: 5.357

Review 4.  Impaired attention, genetics, and the pathophysiology of schizophrenia.

Authors:  B A Cornblatt; J G Keilp
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

Review 5.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

6.  Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration.

Authors:  Nurith Amitai; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2008-07-11       Impact factor: 4.530

7.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

8.  Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.

Authors:  John L Neumeyer; Nora S Kula; Jack Bergman; Ross J Baldessarini
Journal:  Eur J Pharmacol       Date:  2003-08-08       Impact factor: 4.432

Review 9.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

10.  Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task.

Authors:  Marie-Astrid Pezze; Jeffrey W Dalley; Trevor W Robbins
Journal:  Neuropsychopharmacology       Date:  2006-04-12       Impact factor: 7.853

View more
  21 in total

Review 1.  CNTRICS final animal model task selection: control of attention.

Authors:  C Lustig; R Kozak; M Sarter; J W Young; T W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2012-06-06       Impact factor: 8.989

Review 2.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

3.  Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding.

Authors:  S A Barnes; J W Young; S T Bate; J C Neill
Journal:  Behav Brain Res       Date:  2015-11-30       Impact factor: 3.332

4.  Convergent observations of MK-801-induced impairment in rat 5C-CPT performance across laboratories: reversal with a D1 but not nicotinic agonist.

Authors:  Andrew J Grottick; David L MacQueen; Samuel A Barnes; Chris Carroll; Erin K Sanabria; Vishal Bobba; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

5.  Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice.

Authors:  Jordy van Enkhuizen; Dean Acheson; Victoria Risbrough; Sean Drummond; Mark A Geyer; Jared W Young
Journal:  Behav Brain Res       Date:  2013-12-12       Impact factor: 3.332

6.  Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder.

Authors:  Jared W Young; Zackary A Cope; Benedetto Romoli; Esther Schrurs; Jordy van Enkhuizen; Richard F Sharp; Davide Dulcis
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

7.  Dopamine D1-like and D2-like receptors in the dorsal striatum control different aspects of attentional performance in the five-choice serial reaction time task under a condition of increased activity of corticostriatal inputs.

Authors:  Laura Agnoli; Pierangela Mainolfi; Roberto W Invernizzi; Mirjana Carli
Journal:  Neuropsychopharmacology       Date:  2012-11-19       Impact factor: 7.853

Review 8.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

9.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

10.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.